

Supplementary Table 1: Analysis of neutralizing and binding antibodies against SARS-CoV-2 variants on days 14, 28 and 98 post-vaccination boost in the mITT3(98) population.

Variant	PHH-1V (n=410)			BNT162b2 (n=198)		
	Day 14	Day 28	Day 98	Day 14	Day 28	Day 98
Neutralizing antibodies						
Wuhan-Hu-1						
n (%)	407 (99.3)	403 (98.3)	78 (19.0)	193 (97.5)	195 (98.5)	42 (21.2)
GMT	2150.30 [1845.46, 2505.50]	2393.53 [2053.79, 2789.48]	1176.22 [924.71, 1496.14]	3461.11 [2887.46, 4148.72]	3058.96 [2553.30, 3664.76]	986.47 [723.29, 1345.41]
GMT ratio				1.61 [1.35, 1.92]; p<0.0001	1.28 [1.07,1.52]; p=0.0062	0.84 [0.59, 1.20]; p=0.34
GMFR	23.31 [19.96, 27.23]	25.95 [22.21, 30.32]	12.75 [9.50, 17.11]	41.06 [32.80, 51.41]	36.29 [29.01, 45.40]	11.70 [7.83, 17.48]
GMFR ratio				1.76 [1.43, 2.17]; p<0.0001	1.40 [1.14, 1.72]; p=0.0016	0.92 [0.63, 1.34]; p=0.65
Beta						
n (%)	407 (99.3)	403 (98.3)	78 (19.0)	193 (97.5)	195 (98.5)	42 (21.2)
GMT	4738.87 [4072.39, 5514.43]	4107.11 [3528.61, 4780.44]	2015.79 [1572.75, 2583.65]	2381.48 [2344.31, 3419.88]	2574.09 [2132.42, 3107.23]	1098.68 [792.71, 1522.76]
GMT ratio				0.60 [0.49, 0.73]; p<0.0001	0.63 [0.51, 0.77]; p<0.0001	0.55 [0.37, 0.80]; p=0.0022
GMFR	65.91 [56.07, 77.46]	57.12 [48.57,67.17]	28.03 [20.59, 38.17]	46.07 [36.46, 58.20]	41.88 [33.17, 52.87]	17.87 [11.72, 27.25]
GMFR ratio				0.70 [0.56, 0.87]; p=0.0012	0.73 [0.59, 0.91]; p=0.0050	0.64 [0.43, 0.95]; p=0.0261
Delta						
n (%)	407 (99.3)	403 (98.3)	78 (19.0)	193 (97.5)	195 (98.5)	42 (21.2)
GMT	1583.59 [1358.19, 1846.40]	1835.50 [1573.92, 2140.55]	1872.27 [1474.73, 2376.98]	1525.92 [1270.12, 1833.23]	1638.75 [1364.73, 1967.78]	960.35 [705.13, 1307.67]
GMT ratio				0.96 [0.80, 1.16]; p=0.69	0.89 [0.74,1.07]; p=0.22	0.51 [0.36, 0.73]; p=0.0003
GMFR	33.11 [28.45, 38.53]	38.38 [32.96, 44.69]	39.15 [29.31, 52.28]	37.17 [29.84, 46.30]	39.92 [32.07, 49.69]	23.39 [15.76, 34.72]
GMFR ratio				1.12 [0.92, 1.38]; p=0.26	1.04 [0.85, 1.27]; p=0.70	0.60 [0.41, 0.87]; p=0.0065
Omicron BA.1						
n (%)	407 (99.3)	403 (98.3)	78 (19.0)	193 (97.5)	195 (98.5)	42 (21.2)
GMT	2283.10 [1929.00, 2702.21]	1655.48 [1398.44, 1959.77]	650.83 [503.86, 840.70]	1331.54 [1091.36, 1624.56]	998.46 [818.79,1217.55]	357.43 [257.17, 496.78]
GMT ratio				0.58 [0.48, 0.71]; p<0.0001	0.60 [0.50, 0.73]; p<0.0001	0.55 [0.38, 0.80]; p=0.0020
GMFR	68.35 [58.2, 80.24]	49.56 [42.19, 58.22]	19.48 [14.35, 26.46]	46.45 [36.82, 58.59]	34.83 [27.63, 43.90]	12.47 [8.21, 18.93]
GMFR ratio				0.68 [0.55, 0.84]; p<0.0004	0.70 [0.57, 0.87]; p=0.0013	0.64 [0.43, 0.95]; p=0.0257

CI = confidence interval; GMT = Geometric Mean Titre; GMFR = Geometric Mean Fold Rise.

Data are shown for the mITT3(98) population, which includes all subjects in the mITT population without COVID-19 infections reported through Day 98.

n (%), refers to subjects with data; *GMT* is shown as adjusted treatment mean [95% CI]; *GMT ratio* is shown as BNT162b2 active control vs PHH-1V [95% CI] followed by *p*-value for ratio=1. *GMFR* is shown as fold rise of adjusted treatment means between timepoints [95% CI]; *GMFR ratio* is shown as BNT162b2 active control vs PHH-1V [95% CI] followed by *p*-value for ratio=1; *GMFR fold change* is shown for subjects with ≥ 4 -fold change in binding antibodies; *odds* are shown as back-transformed adjusted treatment LS means [95% CI] ; *Treatment effect* is shown for “BNT162b2 vs PHH-1V” as the odds ratio [95% CI] followed by *p*-value for odds ratio=1.